Phase ii evaluation of ftorafur in previously untreated colorectal cancer: A southwest oncology group study
- 1 July 1979
Abstract
Eighty-four previously untreated patients with metastatic adenocarcinoma of the large intestine received intravenous ftorafur at a dosage of 2.25 g/m2/day for 5 consecutive days. Courses were repeated every three weeks. Regressions were noted in 9 of 84 treated patients (11%). Median survival for all patients was 32 weeks. Responders survived only 5 weeks longer than nonresponders; 36 vs. 31 weeks. Central nervous system toxicity was a limiting factor occurring in one-third of patients. Ftorafur in a daily ×5 schedule appears not to make a significant contribution to the management of disseminated colorectal cancer.This publication has 8 references indexed in Scilit:
- PHASE-II TRIAL OF FTORAFUR WITH MITOMYCIN-C VERSUS FTORAFUR WITH METHYL-CCNU IN UNTREATED COLORECTAL CANCER1978
- GLC Determination for Ftorafur in Biological FluidsJournal of Pharmaceutical Sciences, 1977
- PHASE-1 TRIAL OF FTORAFUR COMBINED WITH MITOMYCIN-C OR METHYL-CCNU IN GASTROINTESTINAL CANCERS1977
- Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU.A southwest oncology group studyCancer, 1976
- Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinomaCancer, 1975
- Phase I study of ftorafur, an analog of 5-fluorouracilCancer, 1975
- Results of treatment of malignant tumors with ftorafurCancer, 1972
- 5-Fluorouracil in Cancer: An Improved RegimenAnnals of Internal Medicine, 1970